1 / 33

Teresa Guthrie, Robert Hecht, Yogan Pillay , Mark Blecher, Kelsey Case

Financial Implications of HIV/AIDS in South Africa – the role of the Business Sector Findings from aids2031 costing & the efforts of the National AIDS Spending Assessment 7 Apr 2011 Teresa Guthrie , CEGAA. Teresa Guthrie, Robert Hecht, Yogan Pillay , Mark Blecher, Kelsey Case.

charla
Download Presentation

Teresa Guthrie, Robert Hecht, Yogan Pillay , Mark Blecher, Kelsey Case

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Financial Implications of HIV/AIDS in South Africa – the role of the Business SectorFindings from aids2031 costing & the efforts of the National AIDS Spending Assessment7 Apr 2011Teresa Guthrie, CEGAA Teresa Guthrie, Robert Hecht, Yogan Pillay , Mark Blecher, Kelsey Case

  2. Overview of the Cost Estimates The aids2031 South African costing project was carried out during 2009-2010, sponsored and guided by a national Steering Committee composed of senior South Africa officials and other leading national figures. It was part of a larger international project led by R4D which included the estimation of global costs. It aimed to estimate the long-term costs of various response scenarios till 2031.

  3. Methodology Developed epi baseline & 3 scenarios to 2031 – SPECTRUM parameterised to ASSA outputs to 2016 Collected, reviewed and verified existing costing studies (unit costs) – limited from private sector Obtained current coverage rates for every intervention Received input from the project Steering Committee on current coverage and target rates Agreed on program scale up scenarios with Steering Committee

  4. Methodology (continued) Cost and Epi Projections – for each scenario Epidemiological impact assessed (incidence, mortality, need for treatment, numbers on ART) using Spectrum with Goals Costs estimated using Resource Needs Model (Futures) Resource requirements by program area and intervention For ART & PMTCT incorporated BU-HERO estimates (Meyer Rath, 09) – note that the ART costs have been further adjusted based on the new Tender prices, which will reduce the cost estimates presented here.

  5. The South African Scenarios Narrow NSP by 2011 Expanded NSP by 2021 Hard Choices by 2015 Baseline (maintaining current coverage as comparator)

  6. Scenario 1 – Narrow NSP Political will to achieve universal access is strong Rapid scaling-up of prevention & treatment Achieving key NSP targets by 2011 ART – old WHO regime and 200 CD4 criteria PMTCT single dose till 2009, replaced by dual therapy Early paediatric ART from 2009 No male circumcision

  7. Scenario 2 – Expanded NSP Achievement of all NSP & extra targets by 2021 ART – new regime & CD4 350 eligibility from 2010, 90% reached by 2015/6 MC introduced 2010, reaching 90% by 2021 Expanded workplace programmes, education and behaviour change Mobilization and higher coverage for CSW & MSM Expanded efforts for youth-out-of-school Programs to reduce violence against women Expanded mitigation interventions

  8. Scenario 3 – Hard Choices Resources are limited, focus on scaling up to high levels the most effective prevention interventions; some other prevention and social programs reduced; targets achieved by 2015: same ART effort as under Narrow NSP Increased coverage for Youth in school, condoms, male circumcision, SW & MSMs, STI treatment Maintaining current coverage for VCT & FCG Reduction below NSP targets for: mass media, youth-out of-school, workplace, HBC, palliative care, food parcels, uniforms Mitigation efforts significantly reduced

  9. Estimated Epidemiological Impact

  10. Adult (15+yrs) HIV Prevalence (2000–2031)

  11. Infant HIV-related Deaths (1993 –2031)

  12. Key points from the Epi-projections • Only the expanded NSP will halve the new infections, as per the NSP goal, but only by 2020. • Compared to Baseline, the expanded NSP will avert nearly 6,000 infections in total by 2031, where as continuing with the current NSP will only avert 3,000 – half! • With increasing treatment coverage, HIV prevalence is unlikely to reduce below 10%, best case scenario. • Numbers on treatment will continue to grow, up to 3million by 2018, but thereafter will start to decrease with the expanded NSP & the expanded prevention efforts. • PMTCT will significantly reduce infant mortality, in all scenarios since same coverage.

  13. Estimated Resource Requirements

  14. Total HIV/AIDS Costs by Scenario (2009-2031, ZAR Billions) NB. These estimations include all sectors and all sources of funding DRAFT-do not copy or disseminate

  15. Expanded NSP – Total Resources Required and their Distribution (ZAR billions)

  16. Expanded NSP – Programme Disaggregation (ZAR billions) DRAFT-do not copy or disseminate

  17. Expanded NSP delivery

  18. Cost Implications • With Expanded NSP costs will double from 2010 to 2021 (but will be significantly reduced with new tender prices, should allow for all on at 350CD4 – greater prevention effects) • But thereafter they start to decrease significantly. Treatment taking 60% by 2020, but thereafter reducing. • Largest proportion will be DOH responsibility for the delivery of public ART – therefore important to increase the role of businesses in provision of ART and PMTCT. • Workplace programmes are important for other prevention interventions & Private sector important. • The role of NGOs could be expanded.

  19. Sustainable Funding Sources?

  20. Sources of Financing for HIV/AIDS in SA No SA NASA yet to ascertain current spending trends of all sectors (public, external & private). No comprehensive database of external sources (some from Burlington (2009). No database of business sector CSI activities (some from Trilogue) Budgetary allocations show national spending, conditional grants to provinces & some provincial voted allocations – limited disaggregation. OOPE – unknown. Development partners appear uneasy to share their longer-term commitments to HIV/AIDS in SA? DPs also struggle to provide year-specific expenditures by province. Business sector is not willing to share their expenditure for the NASA process. Therefore impossible to measure the projected financing gap.

  21. SA Public HIV/AIDS Budget Allocations (2006/07-2012/13)

  22. Rough Questimate of Total Resource Gap (for all actors, not only public)

  23. SA DOH Budget Allocations for HIV/AIDS (ZAR millions)

  24. Rough Guestimate of public ART shortfall, assuming 90% coverage by 2015

  25. Importance of the National AIDS Spending Assessment (NASA)

  26. DRAFT - DO NOT DISSEMINATE. Objectives of NASA in South Africa For the years 2007/08, 2008/09 & 2009/10, to identify in each province: All the sources (public, external and private) of financing for HIV/AIDS and TB The providers of the HIV/AIDS and TB services The activities services delivered – and their alignment with the PSP priorities The beneficiaries of the services In order to make recommendations for the improved targeting of funds and efficiency of spending, according to the provincial priorities.

  27. Methodology • Aimed to include data from all sources, from all agents and from sampled service providers. • All DOE, DSD, DOH expenditure by activity and service provider – from BAS records. • Wellness programme spending – included all departments but challenge of coding of HIV-related in BAS records. • All NGOs receiving DOH/ DSD/ EU/ PEPFAR grants – sampled others (but nothing received). • Districts & Municipalities – most included • Donors – Most - EU, GF, UN agencies (NB PEPFAR limitations excl) – pending other donors • Private - Businesses - limited response. Medical aid estimates incld. • Limited research activities • 90% public, 80% external, 80% NGOs & almost no business

  28. Business sector HIV activities in SA MISSING……. ??

  29. Estimating & Securing Resource Requirements • Using estimates of the future costs of an expanded NSP • Comparing current spending per intervention • More detailed and accurate financing gaps can be calculated • Sustainable resources mobilised • This requires all partners to: • participate more actively in the achievement of the Expanded NSP • be transparent about their current and future funding activities • What are the HIV services currently being provided / funded by business? • How could these be expanded? • What does government need to do to encourage business sector involvement?

  30. Acknowledgements WEBSITE: WWW.CEGAA.ORG SANAC, PACs, HASTs, etc UNAIDS Mark Blecher, National Treasury Drs Pillay & Mbengashe (NDOH) aids2031 Steering Committee Gesine Meyer-Rath & Lawrence Long, BU/HERO Kelsey Case, Imperial College London John, Lori & Steve, Futures Institute Leigh Johnson, UCT Susan Cleary, UCT Steve Cohen, SDC All the DoH departments that provided data The teams at CEGAA and Results for Development Institute

More Related